$CSTAF
Constellation Acquisition Corp I Stock $cstaf

$cstaf Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000121390024028020 Filed on March 29, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.202M	$3.560M
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.202M	$65.00K	$238.7K
YoY Change	403.59%	-94.13%	-13.27%
Operating Profit		-$3.560M
YoY Change		221.71%
Interest Expense	$565.7K	$3.026M	$2.623M
YoY Change	-78.43%	-32.36%	43037.01%
% of Operating Profit
Other Income/Expense, Net	$142.2K	$3.200M	$243.3K
YoY Change	-41.56%	-77.12%	-66.45%
Pretax Income	-$494.3K	-$360.5K	$2.627M
YoY Change	-118.81%	-102.8%	475.98%
Income Tax
% Of Pretax Income
Net Earnings	-$494.3K	-$360.5K	$2.627M
YoY Change	-118.81%	-102.8%	475.98%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.02	-$0.03	$0.07
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.540K	$3.540K	$37.74K
YoY Change	-90.62%	-90.62%	-83.11%
Cash & Equivalents	$3.541K		$37.74K
Short-Term Investments
Other Short-Term Assets	$33.41K	$33.41K	$33.45K
YoY Change	-0.12%	-0.12%	-91.74%
Inventory
Prepaid Expenses	$33.41K		$33.45K
Receivables
Other Receivables
Total Short-Term Assets	$36.95K	$36.95K	$71.20K
YoY Change	-48.1%	-48.1%	-88.66%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$49.86M	$49.86M	$314.5M
YoY Change	-84.15%	-84.15%	1.44%
Other Assets			$0.00
YoY Change			-100.0%
Total Long-Term Assets	$49.86M	$49.86M	$314.5M
YoY Change	-84.15%	-84.15%	1.43%
TOTAL ASSETS
Total Short-Term Assets	$36.95K	$36.95K	$71.20K
Total Long-Term Assets	$49.86M	$49.86M	$314.5M
Total Assets	$49.89M	$49.89M	$314.6M
YoY Change	-84.14%	-84.14%	1.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$3.081M	$3.081M	$974.0K
YoY Change	216.29%	216.29%	37.3%
Deferred Revenue
YoY Change
Short-Term Debt	$3.358M	$3.358M	$258.8K
YoY Change	1197.71%	1197.71%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.559M	$6.559M	$1.233M
YoY Change	432.04%	432.04%	73.78%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$11.15M	$11.15M	$11.32M
YoY Change	-1.53%	-1.53%	-45.64%
Total Long-Term Liabilities	$11.15M	$11.15M	$11.32M
YoY Change	-1.53%	-1.53%	-45.64%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.559M	$6.559M	$1.233M
Total Long-Term Liabilities	$11.15M	$11.15M	$11.32M
Total Liabilities	$17.71M	$17.71M	$12.56M
YoY Change	41.03%	41.03%	-41.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.67M		-$12.49M
YoY Change	41.54%		-40.1%
Common Stock			$1.162M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$17.67M	$32.19M	-$12.49M
YoY Change
Total Liabilities & Shareholders Equity	$49.89M	$49.89M	$314.6M
YoY Change	-84.14%	-84.14%	1.25%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income	-$494.3K	-$360.5K	$2.627M
YoY Change	-118.81%	-102.8%	475.98%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$332.7K	-$1.334M	-$80.83K
YoY Change	311.6%	200.09%	-68.97%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$450.0K	$267.7M	$0.00
YoY Change
Cash From Investing Activities	-$450.0K	$267.7M	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$269.5M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	785.0K	-$266.4M	0.000
YoY Change		-103039.3%
NET CHANGE
Cash From Operating Activities	-332.7K	-$1.334M	-80.83K
Cash From Investing Activities	-450.0K	$267.7M	0.000
Cash From Financing Activities	785.0K	-$266.4M	0.000
Net Change In Cash	2.300K	-$34.20K	-80.83K
YoY Change	-102.85%	-81.58%	-68.97%
FREE CASH FLOW
Cash From Operating Activities	-$332.7K	-$1.334M	-$80.83K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39945
CY2023	dei	Entity Registrant Name EntityRegistrantName	CONSTELLATION ACQUISITION CORP I
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1574835
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	200 Park Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	32nd Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10166
CY2023	dei	City Area Code CityAreaCode	(646)
CY2023	dei	Local Phone Number LocalPhoneNumber	585-8975
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Public Float EntityPublicFloat	47544858.94	usd
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2023	dei	Auditor Location AuditorLocation	New York, New York
CY2023	dei	Auditor Firm AuditorFirmId	100
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3541	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37743	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	33411	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	33454	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	36952	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	71197	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	49857596	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	314517268	usd
CY2023Q4	us-gaap	Assets Assets	49894548	usd
CY2022Q4	us-gaap	Assets Assets	314588465	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3080658	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	973996	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6558866	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1232776	usd
CY2023Q4	csta	Deferred Underwriting Fees DeferredUnderwritingFees	10850000	usd
CY2022Q4	csta	Deferred Underwriting Fees DeferredUnderwritingFees	10850000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	300199	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	474000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	17709065	usd
CY2022Q4	us-gaap	Liabilities Liabilities	12556776	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	49857596	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	314517268	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17672888	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12486354	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-17672113	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-12485579	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49894548	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	314588465	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	3440335	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1106700	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-3560335	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1106700	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	3026074	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	4473680	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-173801	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-9509299	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3199875	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	13982979	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-360460	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	12876279	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-20844590	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	4517268	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	12876279	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-12485579	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	4826074	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-360460	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-17672113	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-360460	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	12876279	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	3026074	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	4473680	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-173801	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-9509299	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-43	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-397679	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2106662	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	264606	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1333630	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-444415	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1800000	usd
CY2023	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	269485746	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	267685746	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	269485746	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-266386318	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	258780	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-34202	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-185635	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37743	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	223378	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3541	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37743	usd
CY2021Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	310000000	usd
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.5
CY2023	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	8200000	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	17586741	usd
CY2023	us-gaap	Expense Related To Distribution Or Servicing And Underwriting Fees ExpenseRelatedToDistributionOrServicingAndUnderwritingFees	6200000	usd
CY2023	csta	Deferred Underwriting Fees Payable DeferredUnderwritingFeesPayable	10850000	usd
CY2023	us-gaap	Other Restructuring Costs OtherRestructuringCosts	536741	usd
CY2021Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	310000000	usd
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10
CY2021Q1	us-gaap	Maturity Of Time Deposits MaturityOfTimeDeposits	P185D
CY2021Q1	csta	Percentage Of Public Shareholding To Be Redeemed In Case Business Combination Is Not Consummated PercentageOfPublicShareholdingToBeRedeemedInCaseBusinessCombinationIsNotConsummated	1	pure
CY2023	csta	Shares Issued Price Per Share1 SharesIssuedPricePerShare1	10
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10
CY2023Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	150000	usd
CY2023	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	26506157	shares
CY2023	csta	Trust Account Price Per Share TrustAccountPricePerShare	10.17
CY2023Q4	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	11.5
CY2023Q4	us-gaap	Noninterest Bearing Deposit Liabilities NoninterestBearingDepositLiabilities	55000	usd
CY2023Q4	us-gaap	Deposits Deposits	55000	usd
CY2023Q4	us-gaap	Time Deposits TimeDeposits	605000	usd
CY2024Q1	csta	Aggregate Value AggregateValue	55000	usd
CY2023Q4	csta	Operating Bank Account OperatingBankAccount	3541	usd
CY2023Q4	csta	Working Capital Deficit WorkingCapitalDeficit	3390914	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liability and convertible promissory notes. Such estimates may be subject to change as more current information becomes available and, accordingly, the actual results could differ significantly from those estimates.</p>
CY2023Q4	csta	Proceeds From Cash Withdrawn From Trust Account In Connection With Redemption ProceedsFromCashWithdrawnFromTrustAccountInConnectionWithRedemption	269485746	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Concentration of Credit Risk</b> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts and a Trust Account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition.</p>
CY2023	us-gaap	Insurance Commissions InsuranceCommissions	250000	usd
CY2023Q4	csta	Transaction Costs TransactionCosts	17586741	usd
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	4493843	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	31000000	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	310000000	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	4517268	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	314517268	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	269485746	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	4826074	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	49857596	usd
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	31000000	shares
CY2021Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023	us-gaap	Sale Of Stock Description Of Transaction SaleOfStockDescriptionOfTransaction	In addition, if (x) the Company issues additional Class A Ordinary Shares or equity linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per Class A Ordinary Share (with such issue price or effective issue price to be determined in good faith by the Board and, in the case of any such issuance to the initial shareholders or their affiliates, without taking into account any Founder Shares held by the initial shareholders or such affiliates, as applicable, prior to such issuance including any transfer or reissuance of such shares (the “Newly Issued Price”)), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest, available for the funding of the initial Business Combination, and (z) the volume-weighted average trading price of the Class A Ordinary Shares during the ten (10) trading day period starting on the trading day after the day on which the Company consummates the initial Business Combination is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the market value and the Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger prices adjacent to “Redemption of warrants for Class A Ordinary Shares when the price per Class A Ordinary Share equals or exceeds $10.00.” and “Redemption of warrants for Class A Ordinary Shares when the price per Class A Ordinary Share equals or exceeds $18.00.” will be adjusted (to the nearest cent) to be equal to 100% and 180% of the higher of the market value and the Newly Issued Price, respectively.
CY2023Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10
CY2023Q4	csta	Warrants Price Per Shares WarrantsPricePerShares	0.1
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10
CY2023Q4	us-gaap	Net Asset Value Per Share NetAssetValuePerShare	18
CY2023	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	1125000	shares
CY2021Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	250000	shares
CY2021Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	875000	shares
CY2023	csta	Initial Business Combination InitialBusinessCombination	P1Y
CY2020Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1300	usd
CY2021Q1	csta	Additional Debt Instrument Of Face Amount AdditionalDebtInstrumentOfFaceAmount	88540	usd
CY2021Q1	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	89840	usd
CY2021Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	699999	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	258780	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	227208	usd
CY2022	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	258780	usd
CY2021Q1	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	10000	usd
CY2023	csta	Working Capital Loans WorkingCapitalLoans	1500000	usd
CY2023	csta	Price Paid Per Warrant PricePaidPerWarrant	1.5
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	230000	usd
CY2023	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	150000	usd
CY2023Q1	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	450000	usd
CY2023Q1	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	1270000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3131000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2023	csta	Deferred Underwriting Fees Payable DeferredUnderwritingFeesPayable	10850000	usd
CY2023Q1	us-gaap	Business Combination Consideration Transferred Liabilities Incurred BusinessCombinationConsiderationTransferredLiabilitiesIncurred	3000000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023	csta	Ordinary Shares Outstanding Percentage OrdinarySharesOutstandingPercentage	0.20	pure
CY2023Q4	us-gaap	Deposit Assets DepositAssets	55000	usd
CY2023Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	26415545	usd
CY2023Q4	us-gaap	Noninterest Bearing Deposit Liabilities NoninterestBearingDepositLiabilities	55000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2022	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities		usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001834032

Files In Submission

Name	View Source	Status
0001213900-24-028020-index-headers.html	Edgar Link	pending
0001213900-24-028020-index.html	Edgar Link	pending
0001213900-24-028020.txt	Edgar Link	pending
0001213900-24-028020-xbrl.zip	Edgar Link	pending
csta-20231231.xsd	Edgar Link	pending
ea0202573-10k_constell1.htm	Edgar Link	pending
ea020257301ex10-19_constell1.htm	Edgar Link	pending
ea020257301ex31-1_constell1.htm	Edgar Link	pending
ea020257301ex31-2_constell1.htm	Edgar Link	pending
ea020257301ex32-1_constell1.htm	Edgar Link	pending
ea020257301ex32-2_constell1.htm	Edgar Link	pending
ea020257301ex4-1_constell1.htm	Edgar Link	pending
ea020257301ex97-1_constell1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
csta-20231231_def.xml	Edgar Link	unprocessable
csta-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0202573-10k_constell1_htm.xml	Edgar Link	completed
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
csta-20231231_cal.xml	Edgar Link	unprocessable
csta-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSTAF
Constellation Acquisition Corp I Stock $cstaf

2023 Q4 Form 10-K Financial Statement

#000121390024028020 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSTAF Constellation Acquisition Corp I Stock $cstaf

2023 Q4 Form 10-K Financial Statement

#000121390024028020 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSTAF
Constellation Acquisition Corp I Stock $cstaf